Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Bans Using DEG In Toothpaste, But Denies Possible Health Problem

This article was originally published in PharmAsia News

Executive Summary

A month after saying levels of diethylene glycol found in toothpaste imported from China do not cause health problems, China has banned firms in the country from using DEG as a toothpaste ingredient, citing bans by the U.S. and other countries on sales of toothpaste products containing the chemical

You may also be interested in...



Toothpaste Recalls Bear Out FDA Warning On DEG Contamination

Firms in Florida, New Jersey and Puerto Rico initiated recalls of toothpaste products possibly contaminated with diethylene glycol after FDA warned consumers not to use toothpaste labeled as made in China and issued an import alert to prevent toothpaste containing toxic DEG from entering the country

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel